A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia

被引：19

作者：

Li, Ying ^{[1
,2
]}

Zhu, Demei ^{[1
]}

Peng, Yiqiang ^{[3
]}

Tong, Zhaohui ^{[4
]}

Ma, Zhuang ^{[5
]}

Xu, Jinfu ^{[6
]}

Sung, Shenghua ^{[7
]}

Tang, Huaping ^{[8
]}

Xiu, Qingyu ^{[9
]}

Liang, Yongjie ^{[10
]}

Wang, Xiongbiao ^{[11
]}

Lv, Xiaoju ^{[12
]}

Dai, Yuanrong ^{[13
]}

Zhu, Yingqun ^{[14
]}

Qu, Yuejin ^{[15
]}

Xu, Kaifeng ^{[16
]}

Huang, Yijiang ^{[17
]}

Wu, Shiman ^{[18
]}

Lai, Guoxiang ^{[19
]}

Li, Xi ^{[20
]}

Han, Xiaowen ^{[21
]}

Yang, Zegang ^{[22
]}

Sheng, Jifang ^{[23
]}

Liu, Zhuola ^{[24
]}

Li, Hui ^{[25
]}

Chen, Yiqiang ^{[26
]}

Zhu, Huili ^{[27
]}

Zhang, Yingyuan ^{[1
,2
]}

机构：

[1] Fudan Univ, Huashan Hosp, Inst Antibiot, 12 Middle Wulumuqi Rd, Shanghai 200040, Peoples R China

[2] Natl Hlth & Family Planning Commiss, Key Lab Clin Pharmacol Antibiot, Shanghai, Peoples R China

[3] Changsha Cent Hosp, Changsha, Peoples R China

[4] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China

[5] Gen Hosp Northern Theater Command Peoples Liberat, Shenyang, Peoples R China

[6] Shanghai Pulm Hosp, Shanghai, Peoples R China

[7] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China

[8] Qingdao Municipal Hosp, Qingdao, Peoples R China

[9] Shanghai Changzheng Hosp, Shanghai, Peoples R China

[10] Shanghai East Hosp, Shanghai, Peoples R China

[11] Putuo Dist Cent Hosp, Shanghai, Peoples R China

[12] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[13] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China

[14] Third Hosp Changsha, Changsha, Peoples R China

[15] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China

[16] Peking Union Med Coll Hosp, Beijing, Peoples R China

[17] Hainan Prov Peoples Hosp, Haikou, Hainan, Peoples R China

[18] Shanxi Med Univ, Hosp 1, Taiyuan, Peoples R China

[19] Joint Logist Support Force PLA, 900 Hosp, Fuzhou, Peoples R China

[20] Hainan Med Coll, Affiliated Hosp 1, Haikou, Hainan, Peoples R China

[21] Hebei Prov Peoples Hosp, Shijiazhuang, Hebei, Peoples R China

[22] Changde First Peoples Hosp, Changde, Peoples R China

[23] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[24] Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China

[25] Jilin Prov Peoples Hosp, Changchun, Peoples R China

[26] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China

[27] Fudan Univ, Huadong Hosp, Shanghai, Peoples R China

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2021年 / 37卷 / 04期

关键词：

Sitafloxacin; moxifloxacin; community-acquired pneumonia; randomized controlled trial; efficacy; safety;

D O I：

10.1080/03007995.2021.1885362

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives To evaluate the efficacy and safety of oral sitafloxacin versus oral moxifloxacin in the treatment of Chinese adults with community-acquired pneumonia (CAP). Patients and methods This is a multicenter, randomized, open-label, positive-controlled clinical trial (chinadrugtrials.org.cn identifier: CTR20130046). CAP patients received sitafloxacin tablets 100 mg once daily (qd) or 100 mg twice daily (bid) to compare with moxifloxacin tablets 400 mg qd, for 7-10 days. The primary outcome was non-inferiority of sitafloxacin to moxifloxacin in clinical cure rate at test of cure (TOC) visit in per-protocol set (PPS). Results A total of 343 patients were randomized (sitafloxacin 100 mg qd, n = 117; sitafloxacin 100 mg bid, n = 116; moxifloxacin, n = 110), 291 patients were included in the PPS (sitafloxacin 100 mg qd, n = 96; sitafloxacin 100 mg bid, n = 94; moxifloxacin, n = 101). The clinical cure rate was 94.8% in the sitafloxacin 100 mg qd group, 96.8% in the sitafloxacin 100 mg bid group and 95.0% in the moxifloxacin group. At the TOC visit, the microbiological success rate was 97.0% (32/33) in the sitafloxacin 100 mg qd group, 97.1% (34/35) in the sitafloxacin 100 mg bid group and 94.9% (37/39) in the moxifloxacin group in the microbiological evaluable set (MES). The incidence of study-drug-related adverse events (AEs) was 23.3% (27/116) in the sitafloxacin 100 mg qd group, 29.8% (34/114) in the sitafloxacin 100 mg bid group and 28.2% (31/110) in the moxifloxacin group (p > .05). The common AEs related to study drug were dizziness, nausea, diarrhea, increased platelet count and alanine transaminase (ALT) elevation. All the AEs resolved completely after discontinuation of study drug. Conclusion Sitafloxacin 100 mg qd or 100 mg bid for 7-10 days is not inferior to moxifloxacin 400 mg qd for 7-10 days in clinical efficacy for adult CAP patients. Sitafloxacin provides a safety profile comparable to moxifloxacin.

引用

页码：693 / 701

页数：9

共 50 条

[1] The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia
Hoeffken, G
Meyer, HP
Winter, J
Verhoef, L
RESPIRATORY MEDICINE, 2001, 95 (07) : 553 - 564
[2] Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia
Fogarty, C
Grossman, C
Williams, J
Haverstock, D
Church, D
INFECTIONS IN MEDICINE, 1999, 16 (11) : 748 - +
[3] Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin
Al Ramahi, Jamal Wadi
Ramadan, Mustafa
Jaber, Waad
Abushanab, Lamya
Mughrabi, Mohammad
Alshamayleh, Noor
Mulhem, Ahmad
Momani, Dania
Obaidat, Mohammad
Haddad, Ghayda
Khali, Basma
Zahran, Anas
Odat, Esraa
Kufoof, Nadeen
Arabiat, Haneen
Diab, Amr
Anzueto, Antonio
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2018, 12 (10): : 878 - 886
[4] Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors
Sun Tieying
Sun Li
Wang Rongmei
Ren Xiaoping
Sui Dong-jiang
Pu Chun
Ren Yajuan
Liu Ying
Yang Zhuo
Li Fengzhi
CHINESE MEDICAL JOURNAL, 2014, 127 (07) : 1201 - 1205
[5] A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection
Li, Ying
Yin, Yousheng
Peng, Xiaomei
Zheng, Hongguang
Fu, Fajun
Liu, Zhenxiang
Wu, Xiongfei
Wu, Xiaoyan
Zheng, Song
Chen, Nan
He, Leye
Ren, Laicheng
Ni, Zhaohui
Li, Detian
Liang, Peiyu
Lv, Xiaoju
Zhang, Yingyuan
ANNALS OF MEDICINE, 2021, 53 (01) : 217 - 226
[6] Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan
Yamamoto, Yoshihiro
Watanabe, Akira
Goto, Hajime
Matsushima, Toshiharu
Abe, Shosaku
Aoki, Nobuki
Shimokata, Kaoru
Mikasa, Keiichi
Niki, Yoshihito
Kohno, Shigeru
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) : 544 - 551
[7] A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia
Morganroth, J
DiMarco, JP
Anzueto, A
Niederman, MS
Choudhri, SJ
CHEST, 2005, 128 (05) : 3398 - 3406
[8] Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis
Yoshida, Koichiro
Okimoto, Niro
Kishimoto, Michihiro
Fukano, Hiroshi
Hara, Hiroki
Yoneyama, Hirohide
Moriya, Osamu
Kawanishi, Masayoshi
Kimura, Makoto
Matsushima, Toshiharu
Niki, Yoshihito
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2011, 17 (05) : 678 - 685
[9] Comparision of Efficacy and Safety of Moxifloxacin Monotherapy Versus Ceftriaxone Plus Clarithromycin in Hospitalized Adult Community-Acquired Pneumonia (CAP) Patients With Risk Factors
Ozlu, Tevfik
Karahan, Hakan
Bulbul, Yilmaz
Ozsu, Savas
Oztuna, Funda
EURASIAN JOURNAL OF PULMONOLOGY, 2011, 13 (01) : 9 - 13
[10] Clinical Efficacy of Moxifloxacin Versus Comparator Therapies for Community-Acquired Pneumonia Caused by Legionella spp.
Garau, J.
Fritsch, A.
Arvis, P.
Read, R. C.
JOURNAL OF CHEMOTHERAPY, 2010, 22 (04) : 264 - 266

← 1 2 3 4 5 →